Thank you to our speakers, sponsors, and delegates who joined us in June for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Who's Attended in 2024?
Welcome to the Inaugural Cell & Gene Therapy Pricing & Reimbursement Summit!
Cell and gene therapies are reshaping the landscape, offering not just hope but tangible solutions, from curative treatments to sustained remission rates. However, with these ground breaking advancements come significant challenges in ensuring equitable access and navigating complex coverage and payment structures.
This summit brought together leaders from biotech, pharma, healthcare providers, payers, and government agencies to tackle these pressing issues head-on. As we witnessed landmark approvals like Casgevy by Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia by bluebird bio, the potential for transformative treatments is palpable.
We dissected the impacts of recent ground breaking legislative measures, optimize patient access and drive the successful commercial launch of cell and gene therapies.
Together we shaped the future of healthcare.
The World-Class Speaker Faculty For 2024 Included:
2024 Attendees Included:
Our 2024 Partners Included:
What Our Speakers Had to Say:
“Cell and gene therapies are relatively new. The impact of these much-needed therapies within an environment that is changing and evolving, especially post-pandemic, is still being discussed and understood, not only from development, regulatory and patient perspectives but also within the payer and market access landscape. These are interesting and innovative times; I am excited to be a part of moving this conversation forward.”
Manpreet Sidhu, Executive Director, Global Health Economics, Outcomes Research and Epidemiology, Ultragenyx